The activation and expansion of tumor reactive T cells outside a patients body and their subsequent re-infusion (adoptive cell transfer (ACT)) is at this moment the most effective approach to induce objective anti-tumor responses in end-stage metastasized melanoma patients.
This research aims to extend the investigation of the role of vagal activity in cancer prognosis and to test the hypothesized underlying mechanisms in clinical trials.
In this clinical trial, funded by RCT and performed in Melbourne (Australia) and Leuven (Belgium), patients with ovarian or endometrialcarcinoma will undergo frequent blood drawings over a 2 week period to identify the immune cycle followed by oral low dose cyclophosphamide treatment at certain stages of the immune cycle.
A pilot study which investigates if oral bicarbonate as an adjuvant can reduce pain in patients with tumor related pain. Furthermore, a phase 1 study of oral sodium bicarbonate is performed in patients with unresectable pancreatic carcinoma treated with gemcitabine.
The potential differences in overexpression between CYP1A1 and CYP1B1 in human tumors will be evaluated. Because CYP1A1 and CYP1B1 do not seem to be expressed in normal cells, these enzymes could become an important target in cancer therapy.
If you would like to submit a project to RCT that is in line with our vision and mission please send a summary of approx. 500 words to info@reliablecancertherapies [dot] com. RCT is especially interested in research on cancer treatments that put into practice new ideas and methods that could result in a leap frog forward in survival of cancer patients.
More precisely, RCT wants to support these developments that fall outside the focus of the pharmaceutical industry and the institutional research. RCT will continuously select projects for in depth evaluation. In case your project is choosen, a detailed research plan, milestones, timeline and budget will be required for further assessment by a panel of experts.